CORCEPT THERAPEUTICS INC 8-K

What Happened
Corcept Therapeutics (CORT) filed an 8-K reporting results of its May 21, 2026 Annual Meeting. Stockholders approved an amendment to the Corcept Therapeutics 2024 Incentive Award Plan that increases available shares by 8,000,000 and clarifies plan language; the amended plan became effective upon approval. Eight directors were elected to serve through the 2027 annual meeting, Ernst & Young LLP was ratified as the independent registered public accounting firm for 2026, and the company’s named executive officer compensation was approved on an advisory basis.

Key Details

• 107,356,686 shares were entitled to vote; 93,270,175 shares were voted at the meeting.
• Amended 2024 Incentive Award Plan: increase of 8,000,000 shares; shareholder vote: For 53,163,364 / Against 23,867,363 / Abstain 263,730 (15,975,718 broker non-votes).
• Director elections: all eight nominees were elected. Examples of vote totals: Joseph K. Belanoff, M.D. — For 76,965,512; David L. Mahoney — For 51,078,278, Withheld 26,216,179.
• Auditor ratification and advisory pay vote: Ernst & Young LLP ratified For 92,656,473 / Against 569,010; say-on-pay advisory approved For 72,511,429 / Against 4,560,385.

Why It Matters
The approved amendment increases the pool of shares available for future equity awards to employees and directors, which can help retain and incentivize personnel but may lead to further share issuance if awards are granted and vested. Election of the full slate of directors maintains board continuity, and ratification of the auditor completes routine governance matters confirmed by shareholders. Investors should note the vote margins on the incentive plan and certain directors as measures of shareholder sentiment.